FDA Approves Antibiotic Sivextro To Treat Adults With Skin Infections

The Food and Drug Administration June 23 approved the antibiotic Sivextro (tedizolid phosphate) for treating adults with skin infections.

Sivextro is approved to treat patients with acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus [MRSA], and methicillin-susceptible strains), various Streptococcus species and Enterococcus faecalis, the agency said. Sivextro is available for intravenous and oral use.

Sivextro, which is marketed by Cubist Pharmaceuticals Inc., of Lexington, Mass., is the second new antibacterial drug approved by the FDA in the past month to treat ABSSSI. On May 23, the agency ...